{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:25Z","timestamp":1787032765153,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"DOI":"10.7759\/cureus.44097","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T07:48:17Z","timestamp":1692949697000},"source":"Crossref","is-referenced-by-count":6,"title":["Orthostatic Hypotension in Benign Prostatic Hyperplasia Patients and Its Association With Alpha-1 Antagonist Use: A Comprehensive Literature Review"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Abubakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siffat S","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Basavaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazza","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim K","family":"Lateef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Furqan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ather","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Benign prostatic hyperplasia: an overview","volume":"7","author":"Roehrborn CG","year":"2005","unstructured":"Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005, 7:S3-S14.","journal-title":"Rev Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1997.00205.x","article-title":"Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group","volume":"80","author":"Buzelin JM","year":"1997","unstructured":"Buzelin JM, Fonteyne E, Kontturi M, Witjes WP, Khan A. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol. 1997, 80:597-605. 10.1046\/j.1464-410x.1997.00205.x","journal-title":"Br J Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385157-4.00507-8","article-title":"Orthostatic Hypotension","author":"Biaggioni I","year":"2014","unstructured":"Biaggioni I, Kaufmann H. Orthostatic Hypotension. Encyclopedia of the Neurological Sciences (Second Edition). Aminoff MJ, Daroff RB (ed): Academic Press, Elsevier, Cambridge, Massachusetts; 2014. 698-700. 10.1016\/B978-0-12-385157-4.00507-8"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.834879","article-title":"Evaluating the impact of orthostatic syncope and presyncope on quality of life: a systematic review and meta-analysis","volume":"9","author":"Hockin BCD","year":"2022","unstructured":"Hockin BCD, Heeney ND, Whitehurst DGT, Claydon VE. Evaluating the impact of orthostatic syncope and presyncope on quality of life: a systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:834879. 10.3389\/fcvm.2022.834879","journal-title":"Front Cardiovasc Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i25.9142","article-title":"Tamsulosin-induced life-threatening hypotension in a patient with spinal cord injury: a case report","volume":"10","author":"Lee JY","year":"2022","unstructured":"Lee JY, Lee HS, Park SB, Lee KH. Tamsulosin-induced life-threatening hypotension in a patient with spinal cord injury: a case report. World J Clin Cases. 2022, 10:9142-7. 10.12998\/wjcc.v10.i25.9142","journal-title":"World J Clin Cases"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000816","article-title":"Management of orthostatic hypotension","volume":"26","author":"Palma JA","year":"2020","unstructured":"Palma JA, Kaufmann H. Management of orthostatic hypotension. Continuum (Minneap Minn). 2020, 26:154-77. 10.1212\/CON.0000000000000816","journal-title":"Continuum (Minneap Minn)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.010573","article-title":"Orthostatic hypotension: management of a complex, but common, medical problem","volume":"15","author":"Fedorowski A","year":"2022","unstructured":"Fedorowski A, Ricci F, Hamrefors V, et al.. Orthostatic hypotension: management of a complex, but common, medical problem. Circ Arrhythm Electrophysiol. 2022, 15:e010573. 10.1161\/CIRCEP.121.010573","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000223828.28215.0b","article-title":"Delayed orthostatic hypotension: a frequent cause of orthostatic intolerance","volume":"67","author":"Gibbons CH","year":"2006","unstructured":"Gibbons CH, Freeman R. Delayed orthostatic hypotension: a frequent cause of orthostatic intolerance. Neurology. 2006, 67:28-32. 10.1212\/01.wnl.0000223828.28215.0b","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2012.00314","article-title":"Arterial baroreflex control of muscle sympathetic nerve activity under orthostatic stress in humans","volume":"3","author":"Ichinose M","year":"2012","unstructured":"Ichinose M, Nishiyasu T. Arterial baroreflex control of muscle sympathetic nerve activity under orthostatic stress in humans. Front Physiol. 2012, 3:314. 10.3389\/fphys.2012.00314","journal-title":"Front Physiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2015.11.3.220","article-title":"Orthostatic hypotension: mechanisms, causes, management","volume":"11","author":"Low PA","year":"2015","unstructured":"Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol. 2015, 11:220-6. 10.3988\/jcn.2015.11.3.220","journal-title":"J Clin Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.799","article-title":"The selectivity of \u03b1-adrenoceptor agonists for the human \u03b11A, \u03b11B, and \u03b11D-adrenoceptors","volume":"9","author":"Proudman RGW","year":"2021","unstructured":"Proudman RGW, Baker JG. The selectivity of \u03b1-adrenoceptor agonists for the human \u03b11A, \u03b11B, and \u03b11D-adrenoceptors. Pharmacol Res Perspect. 2021, 9:e00799. 10.1002\/prp2.799","journal-title":"Pharmacol Res Perspect"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14617","article-title":"Updates in the function and regulation of \u03b1(1)-adrenoceptors","volume":"176","author":"Akinaga J","year":"2019","unstructured":"Akinaga J, Garc\u00eda-S\u00e1inz JA, S Pupo A. Updates in the function and regulation of \u03b1(1)-adrenoceptors. Br J Pharmacol. 2019, 176:2343-57. 10.1111\/bph.14617","journal-title":"Br J Pharmacol"},{"key":"ref13","unstructured":"Alpha 1 adrenergic receptor antagonists. (2012). Accessed. July 10, 2023: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548719\/."},{"key":"ref14","article-title":"Alpha blockers for the treatment of benign prostatic hyperplasia","volume":"9","author":"Lepor H","year":"2007","unstructured":"Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007, 9:181-90.","journal-title":"Rev Urol"},{"key":"ref15","article-title":"Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia","volume":"7","author":"Narayan P","year":"2005","unstructured":"Narayan P, Tunuguntla HSGR. Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Rev Urol. 2005, 7:S42-8.","journal-title":"Rev Urol"},{"key":"ref16","article-title":"A comparison of varying \u03b1-blockers and other pharmacotherapy options for lower urinary tract symptoms","volume":"7 Suppl 4","author":"Chapple CR","year":"2005","unstructured":"Chapple CR. A comparison of varying \u03b1-blockers and other pharmacotherapy options for lower urinary tract symptoms. Rev Urol. 2005, 7 Suppl 4:S22-30.","journal-title":"Rev Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/1008-682X.154990","article-title":"Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and \u03b1-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH","volume":"17","author":"Wang XH","year":"2015","unstructured":"Wang XH, Wang X, Shi MJ, Li S, Liu T, Zhang XH. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and \u03b1-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J Androl. 2015, 17:1022-32. 10.4103\/1008-682X.154990","journal-title":"Asian J Androl"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1474-8673.1996.tb00352.x","article-title":"Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate","volume":"16","author":"Michel MC","year":"1996","unstructured":"Michel MC, Gr\u00fcbbel B, Taguchi K, Verf\u00fcrth F, Otto T, Kr\u00f6pfl D. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996, 16:21-8. 10.1111\/j.1474-8673.1996.tb00352.x","journal-title":"J Auton Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219020-00004","article-title":"Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms","volume":"19","author":"Dunn CJ","year":"2002","unstructured":"Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002, 19:135-61. 10.2165\/00002512-200219020-00004","journal-title":"Drugs Aging"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/1756287221993283","article-title":"Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis","volume":"13","author":"Mari A","year":"2021","unstructured":"Mari A, Antonelli A, Cindolo L, Fusco F, Minervini A, De Nunzio C. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Ther Adv Urol. 2021, 13:1756287221993283. 10.1177\/1756287221993283","journal-title":"Ther Adv Urol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2003.04309.x","article-title":"Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies","volume":"92","author":"Roehrborn CG","year":"2003","unstructured":"Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003, 92:257-61. 10.1046\/j.1464-410x.2003.04309.x","journal-title":"BJU Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.180024","article-title":"Alfuzosin and its effect on ejaculatory dysfunction: a systematic review","volume":"39","author":"Yeung HEL","year":"2021","unstructured":"Yeung HEL, Sena SJ, Calopedos RJ, Woo HH. Alfuzosin and its effect on ejaculatory dysfunction: a systematic review. World J Mens Health. 2021, 39:186-94. 10.5534\/wjmh.180024","journal-title":"World J Mens Health"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.05.001","article-title":"Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects","volume":"66","author":"MacDonald R","year":"2005","unstructured":"MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology. 2005, 66:780-8. 10.1016\/j.urology.2005.05.001","journal-title":"Urology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01021-9","article-title":"Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin","volume":"57","author":"McNeill SA","year":"2001","unstructured":"McNeill SA, Hargreave TB, Geffriaud-Ricouard C, Santoni JP, Roehrborn CG. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology. 2001, 57:459-65. 10.1016\/S0090-4295(00)01021-9","journal-title":"Urology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.12.1955","article-title":"Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia","volume":"16","author":"Yoshida M","year":"2007","unstructured":"Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007, 16:1955-65. 10.1517\/13543784.16.12.1955","journal-title":"Expert Opin Investig Drugs"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S13803","article-title":"Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia","volume":"6","author":"Yoshida M","year":"2011","unstructured":"Yoshida M, Kudoh J, Homma Y, Kawabe K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging. 2011, 6:161-72. 10.2147\/CIA.S13803","journal-title":"Clin Interv Aging"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2017.02.001","article-title":"Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications","volume":"5","author":"Choi WS","year":"2017","unstructured":"Choi WS, Cho MC, Lee JW, et al.. Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications. Prostate Int. 2017, 5:113-18. 10.1016\/j.prnil.2017.02.001","journal-title":"Prostate Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6320","article-title":"Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology","volume":"347","author":"Bird ST","year":"2013","unstructured":"Bird ST, Delaney JAC, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ. 2013, 347:f6320. 10.1136\/bmj.f6320","journal-title":"BMJ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00126-5","article-title":"Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia","volume":"51","author":"Lepor H","year":"1998","unstructured":"Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998, 51:892-900. 10.1016\/S0090-4295(98)00126-5","journal-title":"Urology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(97)80097-5","article-title":"Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect","volume":"19","author":"Lowe FC","year":"1997","unstructured":"Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther. 1997, 19:730-42. 10.1016\/s0149-2918(97)80097-5","journal-title":"Clin Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/147323000102900312","article-title":"Review of orthostatic tests on the safety of tamsulosin, a selective alpha1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects","volume":"29","author":"Yasukawa K","year":"2001","unstructured":"Yasukawa K, Swarz H, Ito Y. Review of orthostatic tests on the safety of tamsulosin, a selective alpha1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects. J Int Med Res. 2001, 29:236-51. 10.1177\/147323000102900312","journal-title":"J Int Med Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1159\/000052230","article-title":"Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia","volume":"33 Suppl 2","author":"Kirby RS","year":"1998","unstructured":"Kirby RS. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. Eur Urol. 1998, 33 Suppl 2:19-27. 10.1159\/000052230","journal-title":"Eur Urol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.06.072","article-title":"Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study","volume":"74","author":"Marks LS","year":"2009","unstructured":"Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009, 74:1318-22. 10.1016\/j.urology.2009.06.072","journal-title":"Urology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-1044","article-title":"Orthostatic hypotension in older people: considerations, diagnosis and management","volume":"21","author":"Dani M","year":"2021","unstructured":"Dani M, Dirksen A, Taraborrelli P, Panagopolous D, Torocastro M, Sutton R, Lim PB. Orthostatic hypotension in older people: considerations, diagnosis and management. Clin Med (Lond). 2021, 21:e275-82. 10.7861\/clinmed.2020-1044","journal-title":"Clin Med (Lond)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpy050","article-title":"Risk factors for orthostatic hypotension: differences between elderly men and women","volume":"31","author":"M\u00e9ndez AS","year":"2018","unstructured":"M\u00e9ndez AS, Melgarejo JD, Mena LJ, et al.. Risk factors for orthostatic hypotension: differences between elderly men and women. Am J Hypertens. 2018, 31:797-803. 10.1093\/ajh\/hpy050","journal-title":"Am J Hypertens"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000145405.01113.0e","article-title":"Critical role for the alpha-1B adrenergic receptor at the sympathetic neuroeffector junction","volume":"44","author":"Townsend SA","year":"2004","unstructured":"Townsend SA, Jung AS, Hoe YS, et al.. Critical role for the alpha-1B adrenergic receptor at the sympathetic neuroeffector junction. Hypertension. 2004, 44:776-82. 10.1161\/01.HYP.0000145405.01113.0e","journal-title":"Hypertension"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001561","article-title":"Cardiac failure associated with medical therapy of benign prostatic hyperplasia: a population based study","volume":"205","author":"Lusty A","year":"2021","unstructured":"Lusty A, Siemens DR, Tohidi M, Whitehead M, Tranmer J, Nickel JC. Cardiac failure associated with medical therapy of benign prostatic hyperplasia: a population based study. J Urol. 2021, 205:1430-7. 10.1097\/JU.0000000000001561","journal-title":"J Urol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.46.5.1470","article-title":"Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology","volume":"46","year":"1996","unstructured":"Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996, 46.1470. 10.1212\/wnl.46.5.1470","journal-title":"Neurology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2020.1254","article-title":"Orthostatic hypotension in older adults: the role of medications","volume":"90","author":"Rivasi G","year":"2020","unstructured":"Rivasi G, Ungar A. Orthostatic hypotension in older adults: the role of medications. Monaldi Arch Chest Dis. 2020, 90:327-9. 10.4081\/monaldi.2020.1254","journal-title":"Monaldi Arch Chest Dis"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169248","article-title":"Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis","volume":"12","author":"Kim HJ","year":"2017","unstructured":"Kim HJ, Sun HY, Choi H, et al.. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. PLoS One. 2017, 12:e0169248. 10.1371\/journal.pone.0169248","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8375-x","article-title":"The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension","volume":"264","author":"Gibbons CH","year":"2017","unstructured":"Gibbons CH, Schmidt P, Biaggioni I, et al.. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017, 264:1567-82. 10.1007\/s00415-016-8375-x","journal-title":"J Neurol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.06.1084","article-title":"Orthostatic hypotension: epidemiology, prognosis, and treatment","volume":"66","author":"Ricci F","year":"2015","unstructured":"Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol. 2015, 66:848-60. 10.1016\/j.jacc.2015.06.1084","journal-title":"J Am Coll Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1159\/000450642","article-title":"Standing up slowly antagonises initial blood pressure decrease in older adults with orthostatic hypotension","volume":"63","author":"de Bru\u00efne ES","year":"2017","unstructured":"de Bru\u00efne ES, Reijnierse EM, Trappenburg MC, Pasma JH, de Vries OJ, Meskers CG, Maier AB. Standing up slowly antagonises initial blood pressure decrease in older adults with orthostatic hypotension. Gerontology. 2017, 63:137-43. 10.1159\/000450642","journal-title":"Gerontology"},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1992.00400170138025","article-title":"Delayed orthostatic intolerance","volume":"152","author":"Streeten DH","year":"1992","unstructured":"Streeten DH, Anderson GH Jr. Delayed orthostatic intolerance. Arch Intern Med. 1992, 152:1066-72.","journal-title":"Arch Intern Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq451","article-title":"Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06","volume":"32","author":"Healy GN","year":"2011","unstructured":"Healy GN, Matthews CE, Dunstan DW, Winkler EAH, Owen N. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06. Eur Heart J. 2011, 32:590-7. 10.1093\/eurheartj\/ehq451","journal-title":"Eur Heart J"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000000479","article-title":"Effect of prolonged sitting and breaks in sitting time on endothelial function","volume":"47","author":"Thosar SS","year":"2015","unstructured":"Thosar SS, Bielko SL, Mather KJ, Johnston JD, Wallace JP. Effect of prolonged sitting and breaks in sitting time on endothelial function. Med Sci Sports Exerc. 2015, 47:843-9. 10.1249\/MSS.0000000000000479","journal-title":"Med Sci Sports Exerc"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.100.10.1134","article-title":"Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association","volume":"100","author":"Grundy SM","year":"1999","unstructured":"Grundy SM, Benjamin IJ, Burke GL, et al.. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999, 100:1134-46. 10.1161\/01.cir.100.10.1134","journal-title":"Circulation"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-002-0770-6","article-title":"Training mode does not affect orthostatic tolerance in chronically exercising subjects","volume":"89","author":"Franke WD","year":"2003","unstructured":"Franke WD, Mills KK, Lee K, Hernandez JP. Training mode does not affect orthostatic tolerance in chronically exercising subjects. Eur J Appl Physiol. 2003, 89:263-70. 10.1007\/s00421-002-0770-6","journal-title":"Eur J Appl Physiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-002-0024-z","article-title":"Extracellular fluid volume expansion in patients with posturally related syncope","volume":"12","author":"Wieling W","year":"2002","unstructured":"Wieling W, Van Lieshout JJ, Hainsworth R. Extracellular fluid volume expansion in patients with posturally related syncope. Clin Auton Res. 2002, 12:242-9. 10.1007\/s10286-002-0024-z","journal-title":"Clin Auton Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.32.7.1546","article-title":"Muscle tensing during standing: effects on cerebral tissue oxygenation and cerebral artery blood velocity","volume":"32","author":"van Lieshout JJ","year":"2001","unstructured":"van Lieshout JJ, Pott F, Madsen PL, van Goudoever J, Secher NH. Muscle tensing during standing: effects on cerebral tissue oxygenation and cerebral artery blood velocity. Stroke. 2001, 32:1546-51. 10.1161\/01.str.32.7.1546","journal-title":"Stroke"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2003.046029","article-title":"Carotid baroreflex responsiveness to head-up tilt-induced central hypovolaemia: effect of aerobic fitness","volume":"551","author":"Ogoh S","year":"2003","unstructured":"Ogoh S, Volianitis S, Nissen P, Wray DW, Secher NH, Raven PB. Carotid baroreflex responsiveness to head-up tilt-induced central hypovolaemia: effect of aerobic fitness. J Physiol. 2003, 551:601-8. 10.1113\/jphysiol.2003.046029","journal-title":"J Physiol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2003.049205","article-title":"Exercise training and orthostatic intolerance: a paradox?","volume":"551","author":"van Lieshout JJ","year":"2003","unstructured":"van Lieshout JJ. Exercise training and orthostatic intolerance: a paradox?. J Physiol. 2003, 551:401. 10.1113\/jphysiol.2003.049205","journal-title":"J Physiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12249","article-title":"Physical countermeasures to increase orthostatic tolerance","volume":"277","author":"Wieling W","year":"2015","unstructured":"Wieling W, van Dijk N, Thijs RD, de Lange FJ, Krediet CT, Halliwill JR. Physical countermeasures to increase orthostatic tolerance. J Intern Med. 2015, 277:69-82. 10.1111\/joim.12249","journal-title":"J Intern Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12478","article-title":"Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension","volume":"4","author":"Palma JA","year":"2017","unstructured":"Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017, 4:298-308. 10.1002\/mdc3.12478","journal-title":"Mov Disord Clin Pract"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.77a.09118","article-title":"Preventing and treating orthostatic hypotension: as easy as A, B, C","volume":"77","author":"Figueroa JJ","year":"2010","unstructured":"Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med. 2010, 77:298-306. 10.3949\/ccjm.77a.09118","journal-title":"Cleve Clin J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1998.tb01087.x","article-title":"Tilt training: a new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance","volume":"21","author":"Ector H","year":"1998","unstructured":"Ector H, Reybrouck T, Heidb\u00fcchel H, Gewillig M, Van de Werf F. Tilt training: a new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance. Pacing Clin Electrophysiol. 1998, 21:193-6. 10.1111\/j.1540-8159.1998.tb01087.x","journal-title":"Pacing Clin Electrophysiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-386454-3.00714-4","article-title":"Alpha Blockers","author":"Miller SM","year":"2014","unstructured":"Miller SM, Cumpston KL. Alpha Blockers. Encyclopedia of Toxicology (Third Edition). Wexler P (ed): Academic Press, Elsevier, Cambridge, Massachusetts; 2014. 154-5. 10.1016\/B978-0-12-386454-3.00714-4"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615615472","article-title":"Predicting risk of adverse drug reactions in older adults","volume":"7","author":"Lavan AH","year":"2016","unstructured":"Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016, 7:11-22. 10.1177\/2042098615615472","journal-title":"Ther Adv Drug Saf"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2005.05300.x","article-title":"Alpha1-adrenergic blockers: current usage considerations","volume":"7","author":"Sica DA","year":"2005","unstructured":"Sica DA. Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich). 2005, 7:757-62. 10.1111\/j.1524-6175.2005.05300.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2007.3.1.181","article-title":"Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)","volume":"3","author":"Cambio AJ","year":"2007","unstructured":"Cambio AJ, Evans CP. Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Ther Clin Risk Manag. 2007, 3:181-96. 10.2147\/tcrm.2007.3.1.181","journal-title":"Ther Clin Risk Manag"},{"key":"ref61","article-title":"Chapter 17. Modified-Release Drug Products","year":"2012","unstructured":"Chapter 17. Modified-Release Drug Products. Applied Biopharmaceutics & Pharmacokinetics, 6e. Shargel L, Wu-Pong S, Yu AC (ed). McGraw-Hill Education, New York City; 2012."},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.522","article-title":"Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: use of stable isotope methodology","volume":"55","author":"Polepally AR","year":"2015","unstructured":"Polepally AR, Remmel RP, Brundage RC, Leppik IE, Rarick JO, Ramsay RE, Birnbaum AK. Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: use of stable isotope methodology. J Clin Pharmacol. 2015, 55:1101-8. 10.1002\/jcph.522","journal-title":"J Clin Pharmacol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1159\/000052361","article-title":"Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group","volume":"37","author":"van Kerrebroeck P","year":"2000","unstructured":"van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000, 37:306-13. 10.1159\/000052361","journal-title":"Eur Urol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s86","article-title":"Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy","volume":"4","author":"Neill MG","year":"2008","unstructured":"Neill MG, Shahani R, Zlotta AR. Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Ther Clin Risk Manag. 2008, 4:11-18. 10.2147\/tcrm.s86","journal-title":"Ther Clin Risk Manag"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002030","article-title":"Clinical implications of delayed orthostatic hypotension: a 10-year follow-up study","volume":"85","author":"Gibbons CH","year":"2015","unstructured":"Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension: a 10-year follow-up study. Neurology. 2015, 85:1362-7. 10.1212\/WNL.0000000000002030","journal-title":"Neurology"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0119-5","article-title":"Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome","volume":"21","author":"Freeman R","year":"2011","unstructured":"Freeman R, Wieling W, Axelrod FB, et al.. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011, 21:69-72. 10.1007\/s10286-011-0119-5","journal-title":"Clin Auton Res"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2013.04.006","article-title":"Evaluation and treatment of orthostatic hypotension","volume":"7","author":"Shibao C","year":"2013","unstructured":"Shibao C, Lipsitz LA, Biaggioni I. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013, 7:317-24. 10.1016\/j.jash.2013.04.006","journal-title":"J Am Soc Hypertens"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/180675-orthostatic-hypotension-in-benign-prostatic-hyperplasia-patients-and-its-association-with-alpha-1-antagonist-use-a-comprehensive-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:57:17Z","timestamp":1707490637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/180675-orthostatic-hypotension-in-benign-prostatic-hyperplasia-patients-and-its-association-with-alpha-1-antagonist-use-a-comprehensive-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":67,"URL":"https:\/\/doi.org\/10.7759\/cureus.44097","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}